Association between circulating concentrations of 25(OH)D and colorectal adenoma: A pooled analysis

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2980-2988

  Jacobs, Elizabeth T ^a,b   Hibler, Elizabeth A ^a,b   Lance, Peter ^a   Sardo, Christine L ^b   Jurutka, Peter W ^c,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

25(OH)D; colon cancer; colorectal adenoma; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; COLORECTAL ADENOMA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIETARY FIBER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR RECURRENCE; VITAMIN BLOOD LEVEL; WHEAT BRAN;

25(OH)D; COLON CANCER; COLORECTAL ADENOMA; VITAMIN D;

ADENOMA; AGED; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROSPECTIVE STUDIES; VITAMIN D;

EID: 84885659218     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28316     Document Type: Article

References (50)

1. Haussler MR, Whitfield GK, Kaneko I, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int 2013; 92: 77-98.
2. Platz EA, Hankinson SE, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomarkers Prev 2000; 9: 1059-65.
3. Levine AJ, Harper JM, Ervin CM, et al. Serum 25-hydroxyvitamin D, dietary calcium intake, and distal colorectal adenoma risk. Nutr Cancer 2001; 39: 35-41.
4. Takahashi R, Mizoue T, Otake T, et al. Circulating vitamin D and colorectal adenomas in Japanese men. Cancer Sci 2010; 101: 1695-700.
5. Adams SV, Newcomb PA, Burnett-Hartman AN, et al. Circulating 25-hydroxyvitamin-D and risk of colorectal adenomas and hyperplastic polyps. Nutr Cancer 2011; 63: 319-26.
6. Zheng XE, Lipka S, Li T, et al. The relationship of vitamin D status, smoking, and colorectal adenoma: A retrospective study in an ethnically diverse community. J Steroid Biochem, doi: 10.1016/j.jsbmb.2012.09.018, in press.
7. LePane CA, Singh G, Spanier-Stiasny JA, et al. Implications of serum 25-hydroxyvitamin D on the prevalence of neoplastic polyps: a cross-sectional study. Gastroenterol Res 2011; 4: 43-50.
8. Yin L, Grandi N, Raum E, et al. Meta-analysis: serum vitamin D and colorectal adenoma risk. Prev Med 2011; 53: 10-6.
9. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128: 1414-24.
10. Wei MY, Garland CF, Gorham ED, et al. Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2008; 17: 2958-69.
11. Gorham ED, Garland CF, Garland FC, et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med 2007; 32: 210-6.
12. Yin L, Grandi N, Raum E, et al. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther 2009; 30: 113-25.
13. Peters U, Hayes RB, Chatterjee N, et al. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 546-52.
14. Jacobs ET, Alberts DS, Benuzillo J, et al. Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. J Steroid Biochem 2007; 103: 752-6.
15. Peehl DM, Skowronski RJ, Leung GK, et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805-10.
16. Frampton RJ, Omond SA, Eisman JA,. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res 1983; 43: 4443-7.
17. Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 2001; 154: 369-87.
18. Wong NA, Pignatelli M,. Beta-catenin-a linchpin in colorectal carcinogenesis? Am J Pathol 2002; 160: 389-401.
19. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N Engl J Med 2000; 342: 1156-62.
20. Alberts DS, Martínez ME, Hess LH, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97: 846-53.
21. Block G, Hartman AM, Naughton D,. A reduced dietary questionnaire: development and validation. Epidemiology 1990; 1: 58-64.
22. Ritenbaugh C, Aickin M, Taren D, et al. Use of a food frequency questionnaire to screen for dietary eligibility in a randomized cancer prevention phase III trial. Cancer Epidemiol Biomarkers Prev 1997; 6: 347-54.
23. Hollis BW,. Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. Methods Enzymol 1997; 282: 174-86.
24. Malabanan A, Veronikis IE, Holick MF,. Redefining vitamin D insufficiency. Lancet 1998; 351: 805-6.
25. Hollis BW,. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr 2005; 135: 317-22.
26. Peters U, McGlynn KA, Chatterjee N, et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001; 10: 1267-74.
27. Miller EA, Keku TO, Satia JA, et al. Calcium, dietary, and lifestyle factors in the prevention of colorectal adenomas. Cancer 2007; 109: 510-7.
28. Fedirko V, Bostick RM, Goodman M, et al. Blood 25-hydroxyvitamin D3 concentrations and incident sporadic colorectal adenoma risk: a pooled case-control study. Am J Epidemiol 2010; 172: 489-500.
29. Hong SN, Kim JH, Choe WH, et al. Circulating vitamin D and colorectal adenoma in asymptomatic average-risk individuals who underwent first screening colonoscopy: a case-control study. Dig Dis Sci 57: 753-63.
30. Yamaji T, Iwasaki M, Sasazuki S, et al. Association between plasma 25-hydroxyvitamin D and colorectal adenoma according to dietary calcium intake and vitamin D receptor polymorphism. Am J Epidemiol 2012; 175: 236-44.
31. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989; 2: 1176-8.
32. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004; 13: 1502-8.
33. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. New Engl J Med 2006; 354: 684-96.
34. Woolcott CG, Wilkens LR, Nomura AM, et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 2010; 19: 130-4.
35. Jenab M, Bueno-de-Mesquita HB, Ferrari P, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. Br Med J 2010; 340: b5500.
36. Tangrea J, Helzlsouer K, Pietinen P, et al. Serum levels of vitamin D metabolites and the subsequent risk of colon and rectal cancer in Finnish men. Cancer Causes Control 1997; 8: 615-25.
37. Wu K, Feskanich D, Fuchs CS, et al. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst 2007; 99: 1120-9.
38. Lee JE, Li H, Chan AT, et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res 2011; 4: 735-43.
39. Braun MM, Helzlsouer KJ, Hollis BW, et al. Colon cancer and serum vitamin D metabolite levels 10-17 years prior to diagnosis. Am J Epidemiol 1995; 142: 608-11.
40. Otani T, Iwasaki M, Sasazuki S, et al. Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. Br J Cancer 2007; 97: 446-51.
41. Shabahang M, Buras RR, Davoodi F, et al. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 1993; 53: 3712-8.
42. Wang QM, Jones JB, Studzinski GP,. Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. Cancer Res 1996; 56: 264-7.
43. Holt PR, Arber N, Halmos B, et al. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol Biomarkers Prev 2002; 11: 113-9.
44. Cross HS, Bareis P, Hofer H, et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001; 66: 287-92.
45. Matusiak D, Benya RV,. CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J Histochem Cytochem 2007; 55: 1257-64.
46. Cross HS, Nittke T, Kallay E,. Colonic vitamin D metabolism: implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. Mol Cell Endocrinol 2011; 347: 70-9.
47. Lao VV, Grady WM,. Epigenetics and colorectal cancer. Nature Rev Gastroentrol Hepatol 2011; 8: 686-700.
48. Cross HS, Kallay E, Lechner D, et al. Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J Nutr 2004; 134: 1207S-12S.
49. Bufill JA,. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Int Med 1990; 113: 779-88.
50. Gervaz P, Bucher P, Morel P,. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol 2004; 88: 261-6.